glp-1 receptor agonists adverse effects Your guide to side Clinical Focus on GLP-1 Agonists

GLP-1/glucagon receptor co-agonism for treatment of obesity

But having diabetes also puts a person at increased risk for developing gastroparesis, so its difficult to know if the risks would look the same for people who dont have the condition

Masharani U, Kroon L (2024): Pancreatic Hormones & Antidiabetic Drugs (Chapter 41)

From 2004 to 2009, an analysis of the database revealed a six-fold increase in pancreatitis incidents linked to the DPP-4 inhibitor sitagliptin and the GLP-1 mimetic exenatide, the first two GLP-1-based medications marketed in the US [51]

By week 12, approximately 85% of users report minimal to no ongoing side effects

Bezin J., Gouverneur A., Pnichon M., et al., GLP1 Receptor Agonists and the Risk of Thyroid Cancer, Diabetes Care 46 (2022): 384390